×
About 46,310 results

ALLMedicine™ Diarrhea Center

Research & Reviews  11,858 results

Rotavirus and the web: analysis of online conversations in Italy during 2020.
https://doi.org/10.1080/21645515.2021.2002087
Human Vaccines & Immunotherapeutics; Marchetti F, Verazza S et. al.

Dec 4th, 2021 - Rotavirus is the most common cause of severe diarrhea among children worldwide. In 2017, Italy included rotavirus vaccination in its National Immunization Program. The use of social media monitoring, an efficient tool to understand vaccine hesitan...

Auranofin for Giardia Protozoa
https://clinicaltrials.gov/ct2/show/NCT02736968

Dec 3rd, 2021 - This is a phase IIa, randomized, placebo-controlled, single-blinded superiority treatment study in males and non-pregnant females, 18 to 65 years of age who are in good health. This study is designed to compare placebo to once daily doses of 6mg a...

Financially-Incentives to Improve Provider Compliance
https://clinicaltrials.gov/ct2/show/NCT04634019

Dec 3rd, 2021 - The main idea of the intervention is to conduct quarterly provider knowledge assessments at health facilities and to pay facilities a bonus if providers perform well on these tests. For the intervention, 12 clinical vignettes were created. These v...

see more →

Guidelines  17 results

ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides diffici...
https://doi.org/10.14309/ajg.0000000000001278 10.1016/j.cgh.2020.06.051
The American Journal of Gastroenterology; Kelly CR, Fischer M et. al.

May 19th, 2021 - Clostridioides difficile infection occurs when the bacterium produces toxin that causes diarrhea and inflammation of the colon. These guidelines indicate the preferred approach to the management of adults with C. difficile infection and represent ...

AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review.
https://doi.org/10.1053/j.gastro.2020.06.090
Gastroenterology Quigley EM, Murray JA et. al.

Jul 18th, 2020 - Thanks to ready access to hydrogen breath testing, small intestinal bacterial overgrowth is now commonly diagnosed among individuals presenting with a variety of gastrointestinal and even non-gastrointestinal complaints and is increasingly implica...

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
https://doi.org/10.6004/jnccn.2020.0012
Journal of the National Comprehensive Cancer Network : JN... Thompson JA, Schneider BJ et. al.

Mar 7th, 2020 - The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe sympt...

Antimotility agents for the treatment of acute noninfectious diarrhea in critically ill...
https://doi.org/10.1097/TA.0000000000002449
The Journal of Trauma and Acute Care Surgery; Bugaev N, Bhattacharya B et. al.

Oct 2nd, 2019 - Acute noninfectious diarrhea is a common phenomenon in intensive care unit patients. Multiple treatments are suggested but the most effective management is unknown. A working group of the Eastern Association for the Surgery of Trauma, aimed to eva...

Canadian Association of Gastroenterology Clinical Practice Guideline on the Management ...
https://doi.org/10.1016/j.cgh.2019.08.062
Clinical Gastroenterology and Hepatology : the Official C... Sadowski DC, Camilleri M et. al.

Sep 19th, 2019 - Chronic diarrhea affects about 5% of the population overall. Altered bile acid metabolism is a common but frequently undiagnosed cause. We performed a systematic search of publication databases for studies of assessment and management of bile acid...

see more →

Drugs  1,808 results see all →

Clinicaltrials.gov  595 results

Auranofin for Giardia Protozoa
https://clinicaltrials.gov/ct2/show/NCT02736968

Dec 3rd, 2021 - This is a phase IIa, randomized, placebo-controlled, single-blinded superiority treatment study in males and non-pregnant females, 18 to 65 years of age who are in good health. This study is designed to compare placebo to once daily doses of 6mg a...

Financially-Incentives to Improve Provider Compliance
https://clinicaltrials.gov/ct2/show/NCT04634019

Dec 3rd, 2021 - The main idea of the intervention is to conduct quarterly provider knowledge assessments at health facilities and to pay facilities a bonus if providers perform well on these tests. For the intervention, 12 clinical vignettes were created. These v...

Clinical Characteristics of Acutely Hospitalized Adults With Community-acquired- Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04681963

Nov 29th, 2021 - Currently, pneumonia diagnosis is primarily based on clinical symptoms such as cough, shortness of breath, chest pain, fever and sputum production, combined with X-ray of the lungs, relevant blood tests and microbiological analysis of sputum sampl...

Endpoint Determination Study Protocol
https://clinicaltrials.gov/ct2/show/NCT03459482

Nov 24th, 2021 - The objective of this Endpoint Determination Study is to address key elements regarding a proposed larger clinical study design: Comparing different potential primary outcome measures Demonstrating that an exclusionary diet as determined by elevat...

The Effects of Connective Tissue Manipulation in Primary Dysmenorrhea
https://clinicaltrials.gov/ct2/show/NCT03914014

Nov 23rd, 2021 - Primary dysmenorrhea is defined as cramping pain in the lower abdomen that occurs before or during menstruation without identifiable pelvic pathology. Secondary symptoms include nausea, vomiting, fatigue, back pain, headaches, dizziness, and diarr...

see more →

News  3,935 results

BO-112 Plus Pembrolizumab Improves ORR in Advanced Melanoma After Progression on Anti–PD-1 Therapy
https://www.onclive.com/view/bo-112-plus-pembrolizumab-improves-orr-in-advanced-melanoma-after-progression-on-anti-pd-1-therapy

Dec 1st, 2021 - The addition of BO-112 to pembrolizumab (Keytruda) produced clinical benefit in patients with unresectable malignant melanoma who have experienced disease progression on anti–PD-1 therapy, according to data from the preliminary analysis of the pha...

Retifanlimab Shows Promising Antitumor Activity in Advanced Endometrial Cancer
https://www.onclive.com/view/retifanlimab-shows-promising-antitumor-activity-in-advanced-endometrial-cancer

Dec 1st, 2021 - Retifanlimab (INCMGA 0012) demonstrated encouraging antitumor activity with favorable tolerability in patients with recurrent microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer, according to data from th...

Pembrolizumab/Lenvatinib Approved in Europe for Frontline RCC
https://www.onclive.com/view/pembrolizumab-lenvatinib-approved-in-europe-for-frontline-rcc

Nov 29th, 2021 - The European Commission has approved the combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) for the treatment of patients with advanced renal cell carcinoma (RCC).1 The decision is based on findings from the phase 3 CLEAR (Study 307...

Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced Melanoma
https://www.onclive.com/view/dr-marquez-rodas-on-the-preliminary-efficacy-of-bo-112-pembrolizumab-in-advanced-melanoma

Nov 23rd, 2021 - Iván Márquez Rodas, MD, PhD, coordinator, Heredofamilial Cancer Unit, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial (NCT04570332),...

Enasidenib/Azacitidine Combo Shows Early, Promising Activity in IDH2-Mutant AML
https://www.onclive.com/view/enasidenib-azacitidine-combo-shows-early-promising-activity-in-idh2-mutant-aml

Nov 23rd, 2021 - The combination of enasidenib (Idhifa) plus azacitidine (Onureg) was well tolerated and induced significantly improved response rates compared with azacitidine alone in patients with newly diagnosed, IDH2-mutant acute myeloid leukemia (AML), accor...

see more →

Patient Education  311 results see all →